| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2468-1253(16)30182-0 |
| P698 | PubMed publication ID | 28404135 |
| P50 | author | Mel Krajden | Q6810759 |
| Mark W. Tyndall | Q51002222 | ||
| Nazrul Islam | Q55539024 | ||
| Jean Shoveller | Q89811150 | ||
| Naveed Zafar Janjua | Q39716263 | ||
| P2093 | author name string | Jane A Buxton | |
| Mark Gilbert | |||
| Paul Gustafson | |||
| Jason Wong | |||
| British Columbia Hepatitis Testers Cohort (BC-HTC) team | |||
| P2860 | cites work | A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs | Q24629455 |
| Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
| High incidence of hepatitis C virus reinfection within a cohort of injecting drug users | Q39797179 | ||
| High incidence of hepatitis C virus reinfection in a cohort of injecting drug users | Q40037737 | ||
| Hepatitis C reinfection after sustained virological response | Q40094351 | ||
| Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States | Q40786866 | ||
| The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach? | Q41745288 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs | Q42197246 | ||
| Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance | Q42226574 | ||
| Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial | Q42280281 | ||
| Injection risk behavior among women syringe exchangers in San Francisco | Q42671943 | ||
| A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin | Q42967977 | ||
| Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam | Q42989819 | ||
| Follow-up studies of treatment for hepatitis C virus infection among injection drug users | Q42991341 | ||
| Reinfection with hepatitis C virus following sustained virological response in injection drug users | Q42998179 | ||
| Hepatitis C virus reinfection in injection drug users | Q43032645 | ||
| Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up | Q43036403 | ||
| A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus | Q43041836 | ||
| Surveillance for newly acquired hepatitis C in Australia | Q44826683 | ||
| Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. | Q45352032 | ||
| Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011 | Q57696129 | ||
| Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants | Q28550601 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Distributive syringe sharing among young adult injection drug users in five U.S. cities | Q33280696 | ||
| Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection | Q33650138 | ||
| Protective immunity against hepatitis C: many shades of gray. | Q33759224 | ||
| Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection | Q33929089 | ||
| Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research | Q34116073 | ||
| Protection against persistence of hepatitis C. | Q34126534 | ||
| Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. | Q34396312 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. | Q34652641 | ||
| Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users | Q34795057 | ||
| Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection | Q35846408 | ||
| Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? | Q35860136 | ||
| The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design | Q35883439 | ||
| Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort | Q36082433 | ||
| Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. | Q36089195 | ||
| Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study | Q36148971 | ||
| Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine | Q36717008 | ||
| Beyond equipment distribution in Needle and Syringe Programmes: an exploratory analysis of blood-borne virus risk and other measures of client need. | Q36949977 | ||
| The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) | Q37363491 | ||
| Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study | Q37521046 | ||
| Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals | Q37601315 | ||
| High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. | Q37769280 | ||
| An area-based material and social deprivation index for public health in Québec and Canada. | Q38101693 | ||
| Hepatitis C virus reinfection following treatment among people who use drugs | Q38123941 | ||
| Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. | Q38123942 | ||
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. | Q38123948 | ||
| Can hepatitis C virus infection be eradicated in people who inject drugs? | Q38182241 | ||
| Mixed HCV infection and reinfection in people who inject drugs--impact on therapy | Q38381584 | ||
| P433 | issue | 3 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 200-210 | |
| P577 | publication date | 2016-12-23 | |
| P1433 | published in | The lancet. Gastroenterology & hepatology | Q27727626 |
| P1476 | title | Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study | |
| P478 | volume | 2 |
| Q40075326 | A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia |
| Q59810024 | Care of Patients Following Cure of Hepatitis C Virus Infection |
| Q99609911 | Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes |
| Q92562917 | Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection |
| Q58657169 | Direct-Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype |
| Q55050518 | Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. |
| Q40341762 | Editorial to Martinello et al.'s HCV reinfection incidence among individuals treated for recent infection |
| Q58781532 | Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals |
| Q63915920 | Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy |
| Q64237696 | Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs |
| Q99570687 | HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development |
| Q58775051 | HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era |
| Q93217404 | HIV control programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam |
| Q59357438 | Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers |
| Q42364607 | Hepatitis C cross-genotype immunity and implications for vaccine development |
| Q90656415 | Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients |
| Q38746105 | Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV? |
| Q57092078 | Intelligent Network DisRuption Analysis (INDRA): A targeted strategy for efficient interruption of hepatitis C transmissions |
| Q63684293 | Management of acute HCV infection in the era of direct-acting antiviral therapy |
| Q64928335 | Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. |
| Q56782091 | Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis |
| Q47556691 | Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial |
| Q57193075 | Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States |
| Q92712616 | Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study |
| Q55339576 | The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study. |
| Q55288229 | The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. |
| Q102377409 | The transmissibility of hepatitis C virus: a modelling study in Xiamen City, China |
| Q45305709 | Towards the Elimination of Hepatitis C in the United States |
| Q47274505 | Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era. |
Search more.